Figure 3.

Mutational analysis of conserved cysteine residues in VEGF-B₁₆₇. (A) Schematic illustration of wild-type and mutant forms of VEGF-B₁₆₇. (B) The cysteine mutants were transfected individually or in combination, labeled in the presence of 50 μg/ml heparin, subjected to immunoprecipitation (IP) or VEGFR-1 Ig binding, and analyzed by SDS/PAGE in reducing (R) and nonreducing (NR) conditions. (C) Some of the VEGF-B₁₆₇ mutants were expressed as above and labeled in the presence of 10 μg/ml heparin. The conditioned media were incubated with VEGFR-1-Ig and the bound ligands were subjected to SDS/PAGE under nonreducing conditions.